http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Jul 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Simulations+Plus%2C+Inc.++++For%3A+May+31/26753315.html si-local-file:///var/storage/secattach/20260709/26753315.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Simulations+Plus%2C+Inc.++++For%3A+May+31/26753315.html Thu, 09 Jul 2026 16:11:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Simulations+Plus%2C+Inc.++++For%3A+May+31/26753315.html si-local-file:///var/storage/secattach/20260709/26753315.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Simulations+Plus%2C+Inc.++++For%3A+May+31/26753315.html Thu, 09 Jul 2026 16:11:00 -0400 O.00185913 SLP http://www.streetinsider.com/Earnings/Simulations+Plus+%28SLP%29+Tops+Q3+EPS+by+7c/26753274.html <p>Simulations Plus (NASDAQ: SLP) reported Q3 EPS of $0.30, $0.07 better than the analyst estimate of $0.23. Revenue for the quarter came in at $21.9 million versus the consensus estimate of $20.93 million.</p><p>For earnings history and earnings-related data on Simulations Plus (SLP) <a href="http://www.streetinsider.com/ec_earnings.php?q=SLP">click here</a>.</p> http://www.streetinsider.com/Earnings/Simulations+Plus+%28SLP%29+Tops+Q3+EPS+by+7c/26753274.html Thu, 09 Jul 2026 16:08:01 -0400 SLP http://www.streetinsider.com/Press+Releases/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html <p> RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. </p><p> <b>Third Quarter 2026 Financial Highlights (as compared to third quarter 2025)</b> </p><ul class="bwlistdisc"> <li> Total revenue increased 7% to $21.9 million </li> <li> Software revenue was flat at $12.6 million, representing 58% of total revenue </li> <li> Services revenue increased 20% to $9.3 million, representing 42% of total revenue </li> <li> Gross profit was $15.1 million and gross margin was 69%, compared to $13.0 million and 64% </li> <li> Net income http://www.streetinsider.com/Press+Releases/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html Thu, 09 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/Press+Releases/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html <p> RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. </p><p> <b>Third Quarter 2026 Financial Highlights (as compared to third quarter 2025)</b> </p><ul class="bwlistdisc"> <li> Total revenue increased 7% to $21.9 million </li> <li> Software revenue was flat at $12.6 million, representing 58% of total revenue </li> <li> Services revenue increased 20% to $9.3 million, representing 42% of total revenue </li> <li> Gross profit was $15.1 million and gross margin was 69%, compared to $13.0 million and 64% </li> <li> Net income http://www.streetinsider.com/Press+Releases/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html Thu, 09 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/Business+Wire/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html <p> RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. </p><p> <b>Third Quarter 2026 Financial Highlights (as compared to third quarter 2025)</b> </p><ul class="bwlistdisc"> <li> Total revenue increased 7% to $21.9 million </li> <li> Software revenue was flat at $12.6 million, representing 58% of total revenue </li> <li> Services revenue increased 20% to $9.3 million, representing 42% of total revenue </li> <li> Gross profit was $15.1 million and gross margin was 69%, compared to $13.0 million and 64% </li> <li> Net income http://www.streetinsider.com/Business+Wire/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html Thu, 09 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/Business+Wire/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html <p> RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. </p><p> <b>Third Quarter 2026 Financial Highlights (as compared to third quarter 2025)</b> </p><ul class="bwlistdisc"> <li> Total revenue increased 7% to $21.9 million </li> <li> Software revenue was flat at $12.6 million, representing 58% of total revenue </li> <li> Services revenue increased 20% to $9.3 million, representing 42% of total revenue </li> <li> Gross profit was $15.1 million and gross margin was 69%, compared to $13.0 million and 64% </li> <li> Net income http://www.streetinsider.com/Business+Wire/Simulations+Plus+Reports+Third+Quarter+Fiscal+2026+Financial+Results/26753207.html Thu, 09 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753228.html si-local-file:///var/storage/secattach/20260709/26753228.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753228.html Thu, 09 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753228.html si-local-file:///var/storage/secattach/20260709/26753228.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753228.html Thu, 09 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753134.html si-local-file:///var/storage/secattach/20260709/26753134.html http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753134.html Thu, 09 Jul 2026 16:01:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753134.html si-local-file:///var/storage/secattach/20260709/26753134.html http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Simulations+Plus%2C+Inc.++++For%3A+Jul+09/26753134.html Thu, 09 Jul 2026 16:01:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+06++Filed+by%3A+DiBella+John+Anthony+II/26747577.html si-local-file:///var/storage/secattach/20260708/26747577.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+06++Filed+by%3A+DiBella+John+Anthony+II/26747577.html Wed, 08 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+06++Filed+by%3A+DiBella+John+Anthony+II/26747577.html si-local-file:///var/storage/secattach/20260708/26747577.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+06++Filed+by%3A+DiBella+John+Anthony+II/26747577.html Wed, 08 Jul 2026 16:05:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+01++Filed+by%3A+WOLTOSZ+WALTER+S/26737027.html si-local-file:///var/storage/secattach/20260706/26737027.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+01++Filed+by%3A+WOLTOSZ+WALTER+S/26737027.html Mon, 06 Jul 2026 18:51:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+01++Filed+by%3A+WOLTOSZ+WALTER+S/26737027.html si-local-file:///var/storage/secattach/20260706/26737027.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Simulations+Plus%2C+Inc.++++For%3A+Jul+01++Filed+by%3A+WOLTOSZ+WALTER+S/26737027.html Mon, 06 Jul 2026 18:51:00 -0400 O.00185913 SLP http://www.streetinsider.com/Press+Releases/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Simulations+Plus%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723158.html <p>MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Simulations Plus (NASDAQ: SLP) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Altaris.</p> <p>Click <a href="https://www.globenewswire.com/Tracker?data=1mU0uQlmyFLHDT3pIsn2uuQVWvTkj5b7iv585f0ldRtpAGW6PnmKei1dD5A2u-RC7R7dUt6bQdCzu_7zBrkgcwmV4GMeXwmZwmbjmyaO_3AgPbaxulvdn_RoaT5F9ge7" rel="nofollow" target="_blank">here</a> to learn how to join our investigation and obtain additional information or contact us at <a href="https://www.globenewswire.com/Tracker?data=RB1LBYeizUO-YhfbfTuIRz36g6iSZ07vHTHKtiTkek0499LwQeGT7FvB_z3BJV3TJv0MIRpFK4Wl2SYo1tWpBin79jovNrc2eaOSd7nHE9A=" rel="nofollow" target="_blank">gademi@ademilaw.com</a> or toll-free: 866-264-3995. There is no cost or obligation to you.</p> <p>Simulations Plus shareholders will receive $18.50 per share in an all-cash transaction valued at approximately $375 million. Simulations Plus insiders will receive substantial benefits as part of change http://www.streetinsider.com/Press+Releases/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Simulations+Plus%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723158.html Thu, 02 Jul 2026 05:10:58 -0400 SLP http://www.streetinsider.com/Globe+Newswire/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Simulations+Plus%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723158.html <p>MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Simulations Plus (NASDAQ: SLP) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Altaris.</p> <p>Click <a href="https://www.globenewswire.com/Tracker?data=1mU0uQlmyFLHDT3pIsn2uuQVWvTkj5b7iv585f0ldRtpAGW6PnmKei1dD5A2u-RC7R7dUt6bQdCzu_7zBrkgcwmV4GMeXwmZwmbjmyaO_3AgPbaxulvdn_RoaT5F9ge7" rel="nofollow" target="_blank">here</a> to learn how to join our investigation and obtain additional information or contact us at <a href="https://www.globenewswire.com/Tracker?data=RB1LBYeizUO-YhfbfTuIRz36g6iSZ07vHTHKtiTkek0499LwQeGT7FvB_z3BJV3TJv0MIRpFK4Wl2SYo1tWpBin79jovNrc2eaOSd7nHE9A=" rel="nofollow" target="_blank">gademi@ademilaw.com</a> or toll-free: 866-264-3995. There is no cost or obligation to you.</p> <p>Simulations Plus shareholders will receive $18.50 per share in an all-cash transaction valued at approximately $375 million. Simulations Plus insiders will receive substantial benefits as part of change http://www.streetinsider.com/Globe+Newswire/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Simulations+Plus%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26723158.html Thu, 02 Jul 2026 05:10:58 -0400 SLP http://www.streetinsider.com/SEC+Filings/Form++144++++++++Simulations+Plus%2C+Inc.+++++++++++++++++Filed+by%3A+WOLTOSZ+WALTER+S/26720945.html si-local-file:///var/storage/secattach/20260701/26720945.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Simulations+Plus%2C+Inc.+++++++++++++++++Filed+by%3A+WOLTOSZ+WALTER+S/26720945.html Wed, 01 Jul 2026 16:18:00 -0400 O.00185913 SLP http://www.streetinsider.com/SEC+Filings/Form++144++++++++Simulations+Plus%2C+Inc.+++++++++++++++++Filed+by%3A+WOLTOSZ+WALTER+S/26720945.html si-local-file:///var/storage/secattach/20260701/26720945.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Simulations+Plus%2C+Inc.+++++++++++++++++Filed+by%3A+WOLTOSZ+WALTER+S/26720945.html Wed, 01 Jul 2026 16:18:00 -0400 O.00185913 SLP http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html <p>Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).</p><p>The analyst commented, "We are hosting our third annual Healthcare Services Forum on June 25 in Boston. In this note we review recent financial results, our estimates, investor focus areas and valuation for the three HCIT companies in our coverage universe attending the forum: NRC Health (NRC, MO, $23 PT), OptimizeRx (OPRX, MO, $9 PT) and Healthstream (HSTM, MP). A fourth that was originally scheduled to present, Simulations Plus (SLP, MP), recently announced a go-private transaction with private equity firm Altaris and can http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html Thu, 25 Jun 2026 04:12:24 -0400 HSTM NRC OPRX SLP http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html <p>Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).</p><p>The analyst commented, "We are hosting our third annual Healthcare Services Forum on June 25 in Boston. In this note we review recent financial results, our estimates, investor focus areas and valuation for the three HCIT companies in our coverage universe attending the forum: NRC Health (NRC, MO, $23 PT), OptimizeRx (OPRX, MO, $9 PT) and Healthstream (HSTM, MP). A fourth that was originally scheduled to present, Simulations Plus (SLP, MP), recently announced a go-private transaction with private equity firm Altaris and can http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html Thu, 25 Jun 2026 04:12:24 -0400 HSTM NRC OPRX SLP http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html <p>Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).</p><p>The analyst commented, "We are hosting our third annual Healthcare Services Forum on June 25 in Boston. In this note we review recent financial results, our estimates, investor focus areas and valuation for the three HCIT companies in our coverage universe attending the forum: NRC Health (NRC, MO, $23 PT), OptimizeRx (OPRX, MO, $9 PT) and Healthstream (HSTM, MP). A fourth that was originally scheduled to present, Simulations Plus (SLP, MP), recently announced a go-private transaction with private equity firm Altaris and can http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html Thu, 25 Jun 2026 04:12:24 -0400 HSTM NRC OPRX SLP http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html <p>Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).</p><p>The analyst commented, "We are hosting our third annual Healthcare Services Forum on June 25 in Boston. In this note we review recent financial results, our estimates, investor focus areas and valuation for the three HCIT companies in our coverage universe attending the forum: NRC Health (NRC, MO, $23 PT), OptimizeRx (OPRX, MO, $9 PT) and Healthstream (HSTM, MP). A fourth that was originally scheduled to present, Simulations Plus (SLP, MP), recently announced a go-private transaction with private equity firm Altaris and can http://www.streetinsider.com/Analyst+Comments/NRC+Health+%28NRC%29+Reiterated+at+Market+Outperform+by+Citizens+Ahead+of+Annual+Forum/26687275.html Thu, 25 Jun 2026 04:12:24 -0400 HSTM NRC OPRX SLP http://www.streetinsider.com/Corporate+News/Simulations+Plus+uses+Nvidia+BioNeMo+toolkit+for+drug+development+AI/26677116.html <p>Simulations Plus, Inc. (Nasdaq: SLP) announced it is building the agentic layer of its Composer platform using the Nvidia BioNeMo Agent Toolkit, expanding a collaboration with Nvidia that was first announced in May 2026.</p><p>The integration focuses on two areas. First, Composer agents are expected to use Nvidia Nemotron Parse to extract and structure information from scientific literature, allowing researchers to trace recommendations back to source documents. Second, the companies are jointly developing nvQSP, a project centered on CUDA-optimized ordinary differential equation solvers for quantitative systems pharmacology, intended to run on Nvidia accelerated computing infrastructure.</p><p>The announcement coincided with Nvidia's introduction of http://www.streetinsider.com/Corporate+News/Simulations+Plus+uses+Nvidia+BioNeMo+toolkit+for+drug+development+AI/26677116.html Tue, 23 Jun 2026 09:15:47 -0400 SLP http://www.streetinsider.com/Press+Releases/Simulations+Plus+Advances+Agentic+Drug+Development+with+NVIDIA+BioNeMo+Agent+Toolkit/26677101.html <p class="bwalignc"> <i>New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development</i> </p> <p> RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgithub.com%2Fnvidia-bionemo&amp;esheet=54558273&amp;newsitemid=20260623040671&amp;lan=en-US&amp;anchor=NVIDIA+BioNeMo+Agent+Toolkit&amp;index=1&amp;md5=9d1bcf584b8a13303d6e43e8ec66b0f0" shape="rect">NVIDIA BioNeMo Agent Toolkit</a>. </p><p> The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-accelerated simulation and AI-assisted modeling workflows into agentic drug development. Together, the http://www.streetinsider.com/Press+Releases/Simulations+Plus+Advances+Agentic+Drug+Development+with+NVIDIA+BioNeMo+Agent+Toolkit/26677101.html Tue, 23 Jun 2026 09:15:00 -0400 O.00185913 SLP